MA43580A - L-valinate d'un dérivé d'hydroxypropylthiazolidine carboxamide, sel et forme cristalline polymorphe correspondants - Google Patents
L-valinate d'un dérivé d'hydroxypropylthiazolidine carboxamide, sel et forme cristalline polymorphe correspondantsInfo
- Publication number
- MA43580A MA43580A MA043580A MA43580A MA43580A MA 43580 A MA43580 A MA 43580A MA 043580 A MA043580 A MA 043580A MA 43580 A MA43580 A MA 43580A MA 43580 A MA43580 A MA 43580A
- Authority
- MA
- Morocco
- Prior art keywords
- valinate
- salt
- crystalline form
- polymorphic crystalline
- corresponding polymorphic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Emergency Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662274674P | 2016-01-04 | 2016-01-04 | |
| US14/987,586 US9447055B1 (en) | 2016-01-04 | 2016-01-04 | α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
| US201662395664P | 2016-09-16 | 2016-09-16 | |
| US201662407918P | 2016-10-13 | 2016-10-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43580A true MA43580A (fr) | 2021-05-26 |
Family
ID=57799697
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043549A MA43549A (fr) | 2016-01-04 | 2017-01-04 | Alpha-amino esters de dérivé d'hydroxypropylthiazolidine carboxamide, sel et forme cristalline polymorphe correspondants |
| MA043580A MA43580A (fr) | 2016-01-04 | 2017-01-04 | L-valinate d'un dérivé d'hydroxypropylthiazolidine carboxamide, sel et forme cristalline polymorphe correspondants |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043549A MA43549A (fr) | 2016-01-04 | 2017-01-04 | Alpha-amino esters de dérivé d'hydroxypropylthiazolidine carboxamide, sel et forme cristalline polymorphe correspondants |
Country Status (23)
| Country | Link |
|---|---|
| EP (4) | EP4140988A1 (fr) |
| JP (5) | JP6933322B2 (fr) |
| KR (2) | KR20180100120A (fr) |
| CN (1) | CN108779087A (fr) |
| AU (4) | AU2017205670B2 (fr) |
| CA (2) | CA3009576A1 (fr) |
| DK (2) | DK3400217T3 (fr) |
| EA (1) | EA036990B1 (fr) |
| ES (2) | ES2916835T3 (fr) |
| HR (2) | HRP20220673T1 (fr) |
| HU (2) | HUE058871T2 (fr) |
| IL (4) | IL284912B (fr) |
| LT (2) | LT3397622T (fr) |
| MA (2) | MA43549A (fr) |
| MX (3) | MX2018008304A (fr) |
| PL (2) | PL3397622T3 (fr) |
| PT (2) | PT3397622T (fr) |
| RS (2) | RS63286B1 (fr) |
| SG (4) | SG10202009723PA (fr) |
| SI (2) | SI3397622T1 (fr) |
| UA (2) | UA125377C2 (fr) |
| WO (2) | WO2017118639A1 (fr) |
| ZA (1) | ZA201903769B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA43549A (fr) * | 2016-01-04 | 2021-05-26 | ObsEva SA | Alpha-amino esters de dérivé d'hydroxypropylthiazolidine carboxamide, sel et forme cristalline polymorphe correspondants |
| RU2711615C1 (ru) * | 2019-09-12 | 2020-01-17 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" | Способ лечения эндометриоза на основании экспериментальной модели у крыс |
| JP2022548314A (ja) * | 2019-09-23 | 2022-11-17 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 妊娠を遷延させるためおよび月経または妊娠の合併症の処置の方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3835175A (en) | 1971-03-15 | 1974-09-10 | Research Corp | 9-fluorenylmethanol haloformates, carbonates and thiocarbonates |
| US3839396A (en) | 1971-07-15 | 1974-10-01 | Shionogi & Co | 9-lower alkyl-9-fluorenyl carbonates |
| US4108846A (en) | 1977-02-01 | 1978-08-22 | Hoffmann-La Roche Inc. | Solid phase synthesis with base N alpha-protecting group cleavage |
| SE430885B (sv) | 1980-03-24 | 1983-12-19 | Ferring Ab | Oxytocin-derivat |
| US4508657A (en) | 1982-01-19 | 1985-04-02 | Research Corporation | Peptide synthesis and amino acid blocking agents |
| US4581167A (en) | 1982-01-19 | 1986-04-08 | Research Corporation | Peptide synthesis and amino acid blocking agents |
| DE10075020I2 (de) | 1982-12-21 | 2003-01-09 | Ferring Ab | Vasotocinderivate |
| US4460501A (en) | 1983-08-30 | 1984-07-17 | Research Corporation | Process for the synthesis of peptides utilizing thioxanthylmethyloxycarbonyl dioxides |
| US5370135A (en) * | 1993-10-13 | 1994-12-06 | Biex, Inc. | Use of estriol measurement to monitor tocolytic therapy |
| DE4434488A1 (de) * | 1994-09-14 | 1996-03-21 | Schering Ag | Steroidester und -amide, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
| SE9604341D0 (sv) | 1996-11-26 | 1996-11-26 | Ferring Bv | Hepta-peptide oxytocin analogue |
| IN188411B (fr) * | 1997-03-27 | 2002-09-21 | Yuhan Corp | |
| WO2001092267A2 (fr) * | 2000-05-30 | 2001-12-06 | Ortho-Mcneil Pharmaceutical, Inc. | Medicaments a base de dihydropyridine, compositions et procedes associes |
| GB0130677D0 (en) | 2001-12-21 | 2002-02-06 | Glaxo Group Ltd | Medicaments and novel compounds |
| EP1480998B1 (fr) | 2002-02-27 | 2006-11-22 | Ferring BV | Intermediaires et procedes destines a fabriquer des analogues d'oxytocine heptapeptide |
| CA2477265A1 (fr) * | 2002-03-28 | 2003-10-09 | Applied Research Systems Ars Holding N.V. | Derives de thiazolidine carboxamide utiles en tant que modulateurs du recepteur de prostaglandine f |
| GB0208785D0 (en) * | 2002-04-17 | 2002-05-29 | Medical Res Council | Treatment methtods |
| US7521530B2 (en) * | 2002-06-11 | 2009-04-21 | Universite De Montreal | Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor |
| UA78058C2 (en) | 2002-07-05 | 2007-02-15 | Applied Research Systems | Pyrrolidine derivative as oxitocin antagonists |
| WO2004052899A2 (fr) * | 2002-12-12 | 2004-06-24 | Idenix (Cayman) Limited | Procede de production de nucleosides ramifies en position 2' |
| GB0314738D0 (en) | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Novel compounds |
| GB0414093D0 (en) | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| EP2493874A1 (fr) | 2009-10-30 | 2012-09-05 | Glaxo Group Limited | Nouvelles formes cristallines de (3r,6r) -3- (2, 3 -dihydro- 1h- inden- 2 -yl) - 1 - [ (1r) - 1 - (2, 6 - diméthyl - 3 - pyridinyl) - 2 - (4 -morpholinyl) -2-oxoéthyl]-6- [(1s) - 1 -méthylpropyl]-2,5- pipérazinedione |
| EP2845850A1 (fr) | 2013-09-10 | 2015-03-11 | ObsEva S.A. | Dérivés de pyrrolidine comme antagonistes des récepteurs V1a de vasopressine/oxytocine |
| EP2886107A1 (fr) | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Formules orales de dérivés de pyrrolydine |
| AU2014397706A1 (en) * | 2014-06-16 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Retosiban for the treatment of pre-term labour |
| JP2017519015A (ja) | 2014-07-02 | 2017-07-13 | オブセヴァ エス．エー． | Ｏｔ−ｒ活性に関する疾患を治療するための方法に有用な結晶質の（３ｚ，５ｓ）−５−（ヒドロキシメチル）−１−［（２’−メチル−１，１’−ビフェニル−４−イル）カルボニル］ピロリジン−３−オン о−メチルオキシム |
| ES2716862T3 (es) | 2014-12-22 | 2019-06-17 | Ferring Bv | Terapia con antagonistas del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida |
| MA43549A (fr) * | 2016-01-04 | 2021-05-26 | ObsEva SA | Alpha-amino esters de dérivé d'hydroxypropylthiazolidine carboxamide, sel et forme cristalline polymorphe correspondants |
| US9447055B1 (en) * | 2016-01-04 | 2016-09-20 | Merck Serono S.A. | α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
-
2017
- 2017-01-04 MA MA043549A patent/MA43549A/fr unknown
- 2017-01-04 KR KR1020187018312A patent/KR20180100120A/ko not_active Application Discontinuation
- 2017-01-04 HU HUE17700392A patent/HUE058871T2/hu unknown
- 2017-01-04 PL PL17700391T patent/PL3397622T3/pl unknown
- 2017-01-04 UA UAA201806074A patent/UA125377C2/uk unknown
- 2017-01-04 HR HRP20220673TT patent/HRP20220673T1/hr unknown
- 2017-01-04 HR HRP20220674TT patent/HRP20220674T1/hr unknown
- 2017-01-04 DK DK17700392.8T patent/DK3400217T3/da active
- 2017-01-04 AU AU2017205670A patent/AU2017205670B2/en active Active
- 2017-01-04 ES ES17700392T patent/ES2916835T3/es active Active
- 2017-01-04 LT LTEPPCT/EP2017/050099T patent/LT3397622T/lt unknown
- 2017-01-04 IL IL284912A patent/IL284912B/en unknown
- 2017-01-04 EP EP22152238.6A patent/EP4140988A1/fr active Pending
- 2017-01-04 PL PL17700392T patent/PL3400217T3/pl unknown
- 2017-01-04 SG SG10202009723PA patent/SG10202009723PA/en unknown
- 2017-01-04 EP EP17700391.0A patent/EP3397622B1/fr active Active
- 2017-01-04 LT LTEPPCT/EP2017/050101T patent/LT3400217T/lt unknown
- 2017-01-04 EP EP22153566.9A patent/EP4144351A1/fr active Pending
- 2017-01-04 WO PCT/EP2017/050099 patent/WO2017118639A1/fr active Application Filing
- 2017-01-04 SG SG11201804594YA patent/SG11201804594YA/en unknown
- 2017-01-04 KR KR1020187018929A patent/KR20180099708A/ko not_active Application Discontinuation
- 2017-01-04 EA EA201891095A patent/EA036990B1/ru unknown
- 2017-01-04 SG SG10202009769WA patent/SG10202009769WA/en unknown
- 2017-01-04 AU AU2017205254A patent/AU2017205254B2/en active Active
- 2017-01-04 CA CA3009576A patent/CA3009576A1/fr active Pending
- 2017-01-04 CN CN201780015011.9A patent/CN108779087A/zh active Pending
- 2017-01-04 PT PT177003910T patent/PT3397622T/pt unknown
- 2017-01-04 WO PCT/EP2017/050101 patent/WO2017118641A1/fr active Application Filing
- 2017-01-04 PT PT177003928T patent/PT3400217T/pt unknown
- 2017-01-04 SI SI201731162T patent/SI3397622T1/sl unknown
- 2017-01-04 MX MX2018008304A patent/MX2018008304A/es unknown
- 2017-01-04 RS RS20220548A patent/RS63286B1/sr unknown
- 2017-01-04 CA CA3009573A patent/CA3009573A1/fr active Pending
- 2017-01-04 JP JP2018529634A patent/JP6933322B2/ja active Active
- 2017-01-04 DK DK17700391.0T patent/DK3397622T3/da active
- 2017-01-04 ES ES17700391T patent/ES2915948T3/es active Active
- 2017-01-04 EP EP17700392.8A patent/EP3400217B1/fr active Active
- 2017-01-04 JP JP2018529284A patent/JP7169573B2/ja active Active
- 2017-01-04 SG SG11201804789QA patent/SG11201804789QA/en unknown
- 2017-01-04 MX MX2018008157A patent/MX2018008157A/es unknown
- 2017-01-04 UA UAA201806830A patent/UA125118C2/uk unknown
- 2017-01-04 RS RS20220547A patent/RS63285B1/sr unknown
- 2017-01-04 HU HUE17700391A patent/HUE058872T2/hu unknown
- 2017-01-04 MA MA043580A patent/MA43580A/fr unknown
- 2017-01-04 SI SI201731161T patent/SI3400217T1/sl unknown
-
2018
- 2018-05-31 IL IL259742A patent/IL259742B/en unknown
- 2018-06-26 IL IL260286A patent/IL260286B/en unknown
- 2018-06-29 MX MX2022000154A patent/MX2022000154A/es unknown
-
2019
- 2019-05-24 ZA ZA2019/03769A patent/ZA201903769B/en unknown
-
2021
- 2021-08-05 JP JP2021129297A patent/JP7432284B2/ja active Active
- 2021-08-16 AU AU2021218009A patent/AU2021218009B2/en active Active
- 2021-12-22 IL IL289256A patent/IL289256A/en unknown
-
2022
- 2022-10-18 JP JP2022166814A patent/JP7377588B2/ja active Active
-
2023
- 2023-09-21 AU AU2023233151A patent/AU2023233151A1/en active Pending
- 2023-10-25 JP JP2023183345A patent/JP2024012376A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272555A (en) | New sulfonamide carboxamide compounds | |
| IL273786A (en) | New sulfonamide carboxamide compounds | |
| IL272550A (en) | New sulfonamide carboxamide compounds | |
| IL271716A (en) | New sulfonamide carboxamide compounds | |
| MA46866A (fr) | Une forme cristalline d'un inhibiteur de magl | |
| MA46972A (fr) | Forme polymorphe de sépiaptérine | |
| IL248277A0 (en) | Compounds of the type: 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl-1,3-thiazol-4-yl amides | |
| IL271399A (en) | Methods for the preparation of heterocyclic 3,1-benzodioxole compounds | |
| HK1258964A1 (zh) | 用於製備1，3-苯並間二氧雜環戊烯雜環化合物的方法 | |
| MA46567A (fr) | Formes cristallines de l'éravacycline | |
| MA43580A (fr) | L-valinate d'un dérivé d'hydroxypropylthiazolidine carboxamide, sel et forme cristalline polymorphe correspondants | |
| GB201702610D0 (en) | Trial head | |
| MA48944A (fr) | Forme cristalline de n-butyldéoxygalactonojirimycine | |
| FR3036312B1 (fr) | Patte de derailleur | |
| PL3515454T3 (pl) | Krystaliczna polimorficzna postać 3-hydroksy-4,5-bis-benzyloksy- 6-benzyloksymetylo-2-fenylo-2-okso-2lambda5-[1,2]oksafosfinanu | |
| EP3665144C0 (fr) | Procédé de récupération de 3-methylbut-3-en-1-ol | |
| MA45685A (fr) | Formes cristallines de 4-cyano-n-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide | |
| ITUB20169994A1 (it) | Nuove forme cristalline di farmaci immunomodulatori | |
| MA44471A (fr) | Forme cristalline | |
| MA52458A (fr) | Nouvelles formes cristallines | |
| GB201814433D0 (en) | Cyclists etc clothes etc | |
| ZA201802361B (en) | Pitting head | |
| GB201716349D0 (en) | Dvs | |
| HUP1700542A2 (en) | Nucleosides modified by 5'-linker | |
| FR3050651B3 (fr) | Reacteur de cristallisation |